A new study in the journal Cancer, published by the American Cancer Society concludes that tamoxifen can save lives and decrease medical costs when taken by menopausal women under 55 years of age as a preventive measure against breast cancer.
A first-in-class chemotherapy agent, eribulin, has shown that it significantly improved overall survival (OS) compared with treatment of physician’s choice (TPC) in women with metastatic breast cancer who have received at least two prior treatments.
More than 30 states are now either pursuing or contemplating legislation that will increase healthcare cost transparencies, and three bills relating to cost transparencies were introduced in Congress in 2010. Unfortunately, research on the effects of price transparency on healthcare systems is in its infancy, and little information is available for states to make these important legislative decisions.
Results of a 4-year follow-up of patients on the Herceptin Adjuvant (HERA) trial have been published in March edition of Lancet Oncology.
Axillary lymph node dissections (ALND) remain the standard of care for breast cancer patients that have sentinel lymph node metastases. However, the procedure carries the risk of serious complications such as infection, lymphedema, and seroma.
Esophageal cancer generally has a poor prognosis; while preoperative chemotherapy is recommended, tumors often do not respond to treatment.
After the initial excitement over the potential of RNAi to target any cancer gene, the field is now being viewed with caution and a bit of skepticism. Delivery system issues need to be solved and substantial clinical data of patient responses from early-stage trials need to be shown for the field to look promising.
A meta-analysis study of 3784 clinical trial patients from five clinical trials taking bevacizumab for breast cancer published in the Journal of Clinical Oncology has found that although the incidence for significant heart failure is low, patients have an increased risk of developing significant heart failure.
For the first time, a series of metastatic melanoma (MM) patients have been genetically tested for the constitutively activating BRAF mutation and assessed for its prognostic significance as is routinely done for breast cancer (HER2) and chronic myeloid leukemia (ABL).
The use of oral bisphosphonates, typically used to treat osteoporosis and bone metastases in breast cancer, has recently been found to reduce breast cancer risk.